216 related articles for article (PubMed ID: 34341503)
1. mTOR signaling mediates ILC3-driven immunopathology.
Teufel C; Horvath E; Peter A; Ercan C; Piscuoglio S; Hall MN; Finke D; Lehmann FM
Mucosal Immunol; 2021 Nov; 14(6):1323-1334. PubMed ID: 34341503
[TBL] [Abstract][Full Text] [Related]
2. mTORC2 acts as a gatekeeper for mTORC1 deficiency-mediated impairments in ILC3 development.
Deng YF; Wu ST; Peng HY; Tian L; Li YN; Yang Y; Meng M; Huang LL; Xiong PW; Li SY; Yang QL; Wang LL; Li XY; Li LP; Lu XL; Li XH; Wei YL; Xiao ZH; Yu JH; Deng YC
Acta Pharmacol Sin; 2023 Nov; 44(11):2243-2252. PubMed ID: 37407703
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia enhances ILC3 responses through HIF-1α-dependent mechanism.
Fachi JL; Pral LP; Dos Santos JAC; Codo AC; de Oliveira S; Felipe JS; Zambom FFF; Câmara NOS; Vieira PMMM; Colonna M; Vinolo MAR
Mucosal Immunol; 2021 Jul; 14(4):828-841. PubMed ID: 33446906
[TBL] [Abstract][Full Text] [Related]
4. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
[TBL] [Abstract][Full Text] [Related]
5. mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation.
Ding X; Bloch W; Iden S; Rüegg MA; Hall MN; Leptin M; Partridge L; Eming SA
Nat Commun; 2016 Oct; 7():13226. PubMed ID: 27807348
[TBL] [Abstract][Full Text] [Related]
6. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
[TBL] [Abstract][Full Text] [Related]
7. Dynamic modelling of the PI3K/MTOR signalling network uncovers biphasic dependence of mTORC1 activity on the mTORC2 subunit SIN1.
Ghomlaghi M; Yang G; Shin SY; James DE; Nguyen LK
PLoS Comput Biol; 2021 Sep; 17(9):e1008513. PubMed ID: 34529665
[TBL] [Abstract][Full Text] [Related]
8. Metabolite-Sensing Receptor Ffar2 Regulates Colonic Group 3 Innate Lymphoid Cells and Gut Immunity.
Chun E; Lavoie S; Fonseca-Pereira D; Bae S; Michaud M; Hoveyda HR; Fraser GL; Gallini Comeau CA; Glickman JN; Fuller MH; Layden BT; Garrett WS
Immunity; 2019 Nov; 51(5):871-884.e6. PubMed ID: 31628054
[TBL] [Abstract][Full Text] [Related]
9. Dynamic modeling of signal transduction by mTOR complexes in cancer.
Dorvash M; Farahmandnia M; Mosaddeghi P; Farahmandnejad M; Saber H; Khorraminejad-Shirazi M; Azadi A; Tavassoly I
J Theor Biol; 2019 Dec; 483():109992. PubMed ID: 31493485
[TBL] [Abstract][Full Text] [Related]
10. The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling.
Yoon MS
Nutrients; 2017 Oct; 9(11):. PubMed ID: 29077002
[TBL] [Abstract][Full Text] [Related]
11. Brg1 restrains the pro-inflammatory properties of ILC3s and modulates intestinal immunity.
Qi X; Qiu J; Chang J; Ji Y; Yang Q; Cui G; Sun L; Chai Q; Qin J; Qiu J
Mucosal Immunol; 2021 Jan; 14(1):38-52. PubMed ID: 32612160
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.
Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA
Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870
[TBL] [Abstract][Full Text] [Related]
13. Role of Nutrient-sensing Receptor GPRC6A in Regulating Colonic Group 3 Innate Lymphoid Cells and Inflamed Mucosal Healing.
Hou Q; Huang J; Xiong X; Guo Y; Zhang B
J Crohns Colitis; 2022 Aug; 16(8):1293-1305. PubMed ID: 35134872
[TBL] [Abstract][Full Text] [Related]
14. Structural mechanisms of the mTOR pathway.
Linde-Garelli KY; Rogala KB
Curr Opin Struct Biol; 2023 Oct; 82():102663. PubMed ID: 37572585
[TBL] [Abstract][Full Text] [Related]
15. Acute Experimental Barrier Injury Triggers Ulcerative Colitis-Specific Innate Hyperresponsiveness and Ulcerative Colitis-Type Microbiome Changes in Humans.
Seidelin JB; Bahl MI; Licht TR; Mead BE; Karp JM; Johansen JV; Riis LB; Galera MR; Woetmann A; Bjerrum JT
Cell Mol Gastroenterol Hepatol; 2021; 12(4):1281-1296. PubMed ID: 34118489
[TBL] [Abstract][Full Text] [Related]
16. Control of B lymphocyte development and functions by the mTOR signaling pathways.
Iwata TN; Ramírez-Komo JA; Park H; Iritani BM
Cytokine Growth Factor Rev; 2017 Jun; 35():47-62. PubMed ID: 28583723
[TBL] [Abstract][Full Text] [Related]
17. TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling.
Wang B; Jie Z; Joo D; Ordureau A; Liu P; Gan W; Guo J; Zhang J; North BJ; Dai X; Cheng X; Bian X; Zhang L; Harper JW; Sun SC; Wei W
Nature; 2017 May; 545(7654):365-369. PubMed ID: 28489822
[TBL] [Abstract][Full Text] [Related]
18. Tanc2-mediated mTOR inhibition balances mTORC1/2 signaling in the developing mouse brain and human neurons.
Kim SG; Lee S; Kim Y; Park J; Woo D; Kim D; Li Y; Shin W; Kang H; Yook C; Lee M; Kim K; Roh JD; Ryu J; Jung H; Um SM; Yang E; Kim H; Han J; Heo WD; Kim E
Nat Commun; 2021 May; 12(1):2695. PubMed ID: 33976205
[TBL] [Abstract][Full Text] [Related]
19. Targeting mTOR Signaling in Type 2 Diabetes Mellitus and Diabetes Complications.
Yang L; Zhang Z; Wang D; Jiang Y; Liu Y
Curr Drug Targets; 2022; 23(7):692-710. PubMed ID: 35021971
[TBL] [Abstract][Full Text] [Related]
20. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
